Zagars G K, Pollack A, von Eschenbach A C
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Cancer. 1997 Aug 15;80(4):764-75.
This study attempted to define unfavorable locoregional prostate carcinoma and presents the results of treatment with combined radiation and androgen ablation for these patients.
Of a group of 938 men with clinically localized N0/NX disease treated with radiation alone, an unfavorable category included all men with prostate specific antigen (PSA) > 20 ng/mL and all men with 10 < PSA < or = 20 ng/mL but with Gleason's grade > 7. One hundred and eighty-five such men treated with radiation alone and an additional 100 men with similar disease received radiation with early androgen ablation. A second cohort was comprised of 229 men with lymphadenectomy proven pelvic lymph node metastases, with 185 receiving early androgen ablation alone and 44 receiving androgen ablation and local radiation. The outcomes, with recurrence or rising PSA as the endpoint, were compared among these various treatment groups using multivariate techniques.
Disease outcome with the combined modality treatment was dramatically improved in both cohorts of men. For those with unfavorable N0/NX disease, the failure rate at 5 years decreased from 82% with only radiation therapy to 15% with combined treatment. Likewise, for patients with lymph node disease, the failure rate at 5 years decreased from 58% with only androgen ablation to 10% with combined treatment. For the whole group with unfavorable disease (unfavorable N0/NX and lymph node positive disease) the 6-year failure decreased from 71% with single modality treatment to 13% with bimodality treatment. There was a close relationship between the incidence of lymph node disease and prognostic categories and patients with otherwise unfavorable disease did not have their poor outlook ameliorated by undergoing a negative lymphadenectomy.
Unfavorable locoregional prostate carcinoma can be recognized on the basis of pretreatment PSA level, T category, and Gleason's grade without specific evaluation of pelvic lymph node status. Combined local radiation and androgen ablation for patients with unfavorable disease results in a substantial improvement in disease control compared with that achieved by either modality alone. The authors found no improvement in survival because all groups of men had a normal life expectancy to at least 5 years.
本研究试图定义不良局部区域前列腺癌,并呈现这些患者接受放疗联合雄激素剥夺治疗的结果。
在一组938例仅接受放疗的临床局限性N0/NX疾病男性患者中,不良类别包括所有前列腺特异性抗原(PSA)>20 ng/mL的男性以及所有PSA为10<PSA≤20 ng/mL但Gleason分级>7的男性。185例此类仅接受放疗的男性以及另外100例患有相似疾病的男性接受了早期雄激素剥夺联合放疗。第二个队列由229例经淋巴结清扫证实有盆腔淋巴结转移的男性组成,其中185例仅接受早期雄激素剥夺治疗,44例接受雄激素剥夺及局部放疗。以复发或PSA升高为终点,使用多变量技术对这些不同治疗组的结果进行比较。
在两组男性中,联合治疗方式的疾病结局均有显著改善。对于不良N0/NX疾病患者,5年失败率从单纯放疗时的82%降至联合治疗时的15%。同样,对于有淋巴结疾病的患者,5年失败率从单纯雄激素剥夺时的58%降至联合治疗时的10%。对于整个不良疾病组(不良N0/NX和淋巴结阳性疾病),6年失败率从单模式治疗时的71%降至双模式治疗时的13%。淋巴结疾病的发生率与预后类别之间存在密切关系,并且其他方面有不良疾病的患者并未因接受阴性淋巴结清扫而改善其不良预后。
可根据治疗前PSA水平、T类别和Gleason分级识别不良局部区域前列腺癌,而无需对盆腔淋巴结状态进行特定评估。与单独使用任何一种方式相比,对不良疾病患者采用局部放疗联合雄激素剥夺可显著改善疾病控制。作者未发现生存率有改善,因为所有男性组的预期寿命至少为5年且均正常。